IceCure's ProSense cryoablation system gains momentum as FDA clears it for low-risk breast cancer treatment.

IceCure Medical's ProSense® cryoablation system, the only FDA-cleared minimally invasive treatment for low-risk breast cancer, is gaining clinical adoption and sales momentum in the U.S. following FDA clearance in October 2025. The system was featured at the 2026 American Society of Breast Surgeons meeting, where leading breast surgeons shared positive experiences and discussed its role in reducing treatment intensity. The ASBrS updated guidelines now recommend cryoablation for select low-risk breast cancer patients, reflecting growing evidence of its safety and effectiveness. IceCure expects a 30% increase in U.S. revenue for ProSense® in Q1 2026 compared to the previous year, signaling broader acceptance and potential standard-of-care status for this less invasive treatment option.